Suppr超能文献

双膦酸盐治疗可改变犬类骨矿物质和基质特性及其异质性。

Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.

机构信息

Hospital for Special Surgery, New York, NY 10021, USA.

出版信息

Bone. 2010 Mar;46(3):666-72. doi: 10.1016/j.bone.2009.11.011. Epub 2009 Nov 17.

Abstract

Bone loss and alterations in bone quality are major causes leading to bone fragility in postmenopausal women. Although bisphosphonates are well known to reduce bone turnover and prevent bone loss in postmenopausal osteoporosis, their effects on other bone properties are not fully characterized. Changes in bone mineral and matrix properties may contribute to the anti-fracture efficacy observed with bisphosphonate treatments. The aim of this work was to analyze the effect of a 1-year treatment with either alendronate or risedronate, at low and high doses, on spatially resolved bone material and compositional properties that could contribute to the fracture efficacy of these agents. Distal tibias from 30 normal beagles that had been treated daily for 1 year with oral doses of vehicle (Veh), alendronate (Aln) at 0.2 or 1 mg/kg, and risedronate (Ris) at 0.1 or 0.5 mg/kg were analyzed by Fourier Transform Infrared imaging (FTIRI) to assess the changes in both mineral and matrix properties in discrete bone areas. The widths at half maximum of the pixel histograms for each FTIRI parameter were used to assess the heterogeneity of the bone tissue. Aln and Ris increased the mineral content and the collagen maturity mainly in cancellous bone and at the endocortical surface. Significant differences were observed in the mineral content and in the hydroxyapatite crystallinity distribution in bone tissue, which can contribute to reduced ductility and micro-crack accumulation. No significant differences were observed between low and high dose nor between Aln and Ris treatments. These results show that pharmacologic suppression of bone turnover increases the mineral and matrix bone tissue maturity in normal cancellous and endocortical bone areas where bone turnover is higher. These positive effects for decreased fracture risk are also associated with a loss of bone heterogeneity that could be one factor contributing to increased bone tissue brittleness and micro-crack accumulation.

摘要

骨丢失和骨质量改变是导致绝经后妇女骨脆弱的主要原因。虽然双膦酸盐被广泛认为可以减少绝经后骨质疏松症中的骨转换并预防骨丢失,但它们对其他骨特性的影响尚未完全确定。骨矿物质和基质特性的变化可能有助于解释双膦酸盐治疗的抗骨折疗效。本研究旨在分析 1 年的阿仑膦酸钠或利塞膦酸钠低、高剂量治疗对可能有助于这些药物骨折疗效的空间分辨骨材料和组成特性的影响。对接受每日口服剂量的载体(Veh)、阿仑膦酸钠(Aln)0.2 或 1mg/kg 和利塞膦酸钠(Ris)0.1 或 0.5mg/kg 治疗 1 年的 30 只正常比格犬的远端胫骨进行傅里叶变换红外成像(FTIRI)分析,以评估离散骨区中矿物质和基质特性的变化。每个 FTIRI 参数的像素直方图半最大值宽度用于评估骨组织的异质性。Aln 和 Ris 主要在松质骨和内皮质表面增加了矿物质含量和胶原成熟度。骨组织中的矿物质含量和羟磷灰石结晶度分布存在显著差异,这可能导致韧性降低和微裂纹积累。在低剂量和高剂量之间以及 Aln 和 Ris 治疗之间均未观察到显著差异。这些结果表明,药物抑制骨转换可增加正常松质骨和内皮质骨区域的矿物质和基质骨组织成熟度,而这些区域的骨转换率较高。这些降低骨折风险的积极影响也与骨异质性的丧失有关,这可能是导致骨组织脆性增加和微裂纹积累的因素之一。

相似文献

引用本文的文献

2
Poor bone matrix quality: What can be done about it?骨基质质量差:有何应对之策?
Curr Osteoporos Rep. 2021 Oct;19(5):510-531. doi: 10.1007/s11914-021-00696-6. Epub 2021 Aug 20.

本文引用的文献

1
Is bone quality associated with collagen age?骨质量与胶原年龄有关吗?
Osteoporos Int. 2009 Sep;20(9):1461-70. doi: 10.1007/s00198-009-0904-3. Epub 2009 Mar 28.
2
Unusual mid-shaft fractures during long-term bisphosphonate therapy.长期双磷酸盐治疗期间出现的不寻常中段骨折。
Clin Endocrinol (Oxf). 2010 Feb;72(2):161-8. doi: 10.1111/j.1365-2265.2009.03581.x. Epub 2009 Mar 19.
6
Osteoporosis: how long should we treat?骨质疏松症:我们应该治疗多久?
Curr Opin Endocrinol Diabetes Obes. 2008 Dec;15(6):502-7. doi: 10.1097/MED.0b013e328317ca83.
10
Biomechanical effect of mineral heterogeneity in trabecular bone.松质骨中矿物质异质性的生物力学效应。
J Biomech. 2008 Sep 18;41(13):2793-8. doi: 10.1016/j.jbiomech.2008.07.009. Epub 2008 Aug 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验